Hwail Pharmaceutical Co.Ltd (061250) — Cash Flow-to-Debt Ratio
Hwail Pharmaceutical Co.Ltd (061250) has a Cash Flow-to-Debt Ratio of 1.29x as of September 2025, meaning its operating cash flow of ₩6.82 Billion could theoretically repay 1% of its total liabilities (₩5.29 Billion) in one year. Explore long-term investment intensity of Hwail Pharmaceutical Co.Ltd to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hwail Pharmaceutical Co.Ltd Cash Flow-to-Debt Ratio (2011–2024)
Historical debt coverage capacity for Hwail Pharmaceutical Co.Ltd across 14 annual periods. Also explore balance sheet size of Hwail Pharmaceutical Co.Ltd for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Hwail Pharmaceutical Co.Ltd (2011–2024)
Year-by-year debt coverage analysis for Hwail Pharmaceutical Co.Ltd. For market capitalisation and broader financial context, see how much is Hwail Pharmaceutical Co.Ltd worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.95x | ₩11.63 Billion | ₩12.19 Billion | ▲ +56.8% |
| 2023 | 0.61x | ₩7.02 Billion | ₩11.55 Billion | ▲ +2710.7% |
| 2022 | -0.02x | ₩-233.56 Million | ₩10.02 Billion | ▼ -101.4% |
| 2021 | 1.61x | ₩20.09 Billion | ₩12.49 Billion | ▲ +10321.0% |
| 2020 | -0.02x | ₩-201.69 Million | ₩12.82 Billion | ▼ -108.5% |
| 2019 | 0.18x | ₩3.69 Billion | ₩19.97 Billion | ▼ -42.8% |
| 2018 | 0.32x | ₩7.17 Billion | ₩22.16 Billion | ▼ -0.2% |
| 2017 | 0.32x | ₩8.34 Billion | ₩25.72 Billion | ▼ -2.7% |
| 2016 | 0.33x | ₩9.58 Billion | ₩28.76 Billion | ▲ +299.4% |
| 2015 | -0.17x | ₩-6.90 Billion | ₩41.33 Billion | ▼ -103.2% |
| 2014 | -0.08x | ₩-2.78 Billion | ₩33.85 Billion | ▼ -143.3% |
| 2013 | 0.19x | ₩6.97 Billion | ₩36.71 Billion | ▲ +484.3% |
| 2012 | 0.03x | ₩1.00 Billion | ₩30.92 Billion | ▼ -87.9% |
| 2011 | 0.27x | ₩7.86 Billion | ₩29.24 Billion | — |